Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0013841017
Wed, 23.07.2025
Lonza Group AG
Ad hoc announcement pursuant to Art. 53 LR
In H1 2025, Lonza delivered sales of CHF 3.6 billion with CER1 growth of 19.0% and CORE EBITDA of CHF 1.1 billion, resulting in a margin of 29.6% (+0.4ppts versus H1 2024)
CDMO2 business delivered sales of CHF 3.1 billion with CER growth of 23.1% and CORE EBITDA of CHF 922 million, resulting in a margin o [ … ]
Tue, 27.05.2025
Lonza Group AG
Ad hoc announcement pursuant to Art. 53 LR
The One Lonza organizational structure became effective on 1 April 2025 and comprises three CDMO Business Platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities
Lonza reports 2024 financials for the CDMO Business Platforms for sales, CORE EBITDA, CORE EBITDA margin and CapEx for th [ … ]
Thu, 15.05.2025
Lonza Group AG
Lonza Group AG
/ Key word(s): Personnel
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer 15.05.2025 / 09:00 CET/CEST
Andreas Bohrer has served as Lonza’s Group General Counsel and Company Secretary since 2015
As of 1 July 2025, Andreas joins Lonza’s Executive Committee as Chief Legal & Corpora [ … ]
Fri, 09.05.2025
Lonza Group AG
Lonza Group AG
/ Key word(s): AGMEGM
Lonza Announces Results of the 2025 Annual General Meeting – All Motions Proposed by Board of Directors Approved 09.05.2025 / 16:30 CET/CEST
Jean-Marc Huët was re-elected as Chair of the Board of Directors
Juan Andres, Eric Drapé and David Meline have been elected as Members of the Board [ … ]
Fri, 09.05.2025
Lonza Group AG
Ad hoc announcement pursuant to Art. 53 LR
Strong CDMO1 performance in Q1 2025, in line with expectations for FY 2025
Robust commercial demand in CDMO business with high utilization in early-stage business, Bioscience returning to growth
Tangible recovery and good momentum in Capsules & Health Ingredients (CHI) as expected
CDMO Outlook 2025 [ … ]
Thu, 03.04.2025
Lonza Group AG
Ad hoc announcement pursuant to Art. 53 LR
Annual General Meeting will take place on 9 May 2025 at the Congress Center in Basel, Switzerland
Jean-Marc Huët proposed for re-election as Chair of the Board of Directors
All current Board Members with the exception of Olivier Verscheure are standing for re-election
Three candidates (Juan Andres, Eric [ … ]
Tue, 01.04.2025
Lonza Group AG
Lonza Group AG
/ Key word(s): Miscellaneous
Lonza Implements its Simplified and Streamlined Operating Model 01.04.2025 / 14:00 CET/CEST
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
Previous divisional structure is now replaced with three newly formed CDMO Bus [ … ]
Tue, 01.04.2025
Lonza Group AG
Lonza Group AG
/ Key word(s): Share Buyback
Lonza Completes its Share Buyback Program 01.04.2025 / 07:00 CET/CEST
Basel, Switzerland, 1 April 2025 – Lonza today announced the successful completion of its share buyback program of up to CHF 2 billion which was launched on 3 April 2023. Through the program, Lonza repurchased 4,23 [ … ]
Wed, 29.01.2025
Lonza Group AG
Ad hoc announcement pursuant to Art. 53 LR
In 2024, Lonza delivered sales of CHF 6.6 billion in line with prior year (-0.2% CER1)
CORE EBITDA of CHF 1.9 billion at a margin of 29.0%
The CDMO2 business delivered a strong commercial and operational performance, while Capsules & Health Ingredients (CHI) experienced market headwinds
The propose [ … ]
